[
    {
        "Tissue": "Cholangiocarcinoma",
        "Model": "CTG-0011",
        "RON_Variant": "165",
        "p_RON_Score": "3",
        "RON_Score": "5",
        "Patient_Treatments": "",
        "PDX_Model_TGI": "1. Capecitabine - 79% (500mpk)2. Cisplatin - 74% (5mpk)3. Cisplatin/Gemcitabine - 58% (3.2mpk/60mpk)4. Erlotinib - 52% (35mpk)5. Gemcitabine - 61% (60mpk)6. Oxaliplatin - 42% (6mpk)",
        "Tumor_status": "Primary",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "Not available",
        "Treatment_history": "Naive",
        "Ethnicity": "Caucasian",
        "Alias": "BIL001",
        "Passage": "P6"
    },
    {
        "Tissue": "Cholangiocarcinoma",
        "Model": "CTG-0294",
        "RON_Variant": "165",
        "p_RON_Score": "5",
        "RON_Score": "5",
        "Patient_Treatments": "",
        "PDX_Model_TGI": "",
        "Tumor_status": "Metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "Not available",
        "Treatment_history": "Naive",
        "Ethnicity": "Caucasian",
        "Alias": "PANC-014",
        "Passage": "P4"
    },
    {
        "Tissue": "Cholangiocarcinoma",
        "Model": "CTG-0399",
        "RON_Variant": "165",
        "p_RON_Score": "4",
        "RON_Score": "2",
        "Patient_Treatments": "",
        "PDX_Model_TGI": "1. Cisplatin - 103% (5mpk)2. Gemcitabin - 102% (60mpk)",
        "Tumor_status": "Not available",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "Not available",
        "Treatment_history": "Not available",
        "Ethnicity": "Caucasian",
        "Alias": "UC-060",
        "Passage": "P3"
    },
    {
        "Tissue": "Cholangiocarcinoma",
        "Model": "CTG-0927",
        "RON_Variant": "165",
        "p_RON_Score": "4",
        "RON_Score": "5",
        "Patient_Treatments": "1. Cisplatin/Gemcitabine - No response2. Gemcitabine/Docetaxel/Capecitabine - Responded3. Experimental PARP inhibitor - No Response4. 5-Fluorouracil/Irinotecan - No Response",
        "PDX_Model_TGI": "1. Docetaxel - 68% (20mpk)2. Doxorubicin - 53% (5mpk)3. Lapatinib - 44% (50mpk)4. Oxaliplatin - 37% (4mpk)5. Trastuzumab - 61% (20mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Asian",
        "Alias": "POS-12108A",
        "Passage": "P3"
    },
    {
        "Tissue": "Cholangiocarcinoma",
        "Model": "CTG-0941",
        "RON_Variant": "WT",
        "p_RON_Score": "1",
        "RON_Score": "1",
        "Patient_Treatments": "1. Gemcitabine/Oxaliplatin - No Response",
        "PDX_Model_TGI": "1. Cisplatin/Gemcitabine - 55% (5mpk/100mpk)2. Cyclophosphamide/Epirubicin - 93% (100mpk/5mpk)3. Eribulin - 147% (1mpk)4. Gemcitabine - 33% (25mpk)5. Pazopanib - 87% (100mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Asian",
        "Alias": "POS-12127A",
        "Passage": "P3"
    },
    {
        "Tissue": "Cholangiocarcinoma",
        "Model": "CTG-0997",
        "RON_Variant": "165",
        "p_RON_Score": "4",
        "RON_Score": "3",
        "Patient_Treatments": "1. Cisplatin/Gemcitabine - No Response",
        "PDX_Model_TGI": "1. Gemcitabin - 126% (100mpk)2. Imatinib - 59% (40mpk)3. Pazopanib - 160% (40mpk)4. Trastuzumab - -12% (?mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Asian",
        "Alias": "POS-11042B",
        "Passage": "P4"
    },
    {
        "Tissue": "Cholangiocarcinoma",
        "Model": "CTG-1034",
        "RON_Variant": "165",
        "p_RON_Score": "3",
        "RON_Score": "4",
        "Patient_Treatments": "1. Cisplatin/Gemcitabine - Not available",
        "PDX_Model_TGI": "",
        "Tumor_status": "Metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Asian",
        "Alias": "POS-13050A",
        "Passage": "P3"
    },
    {
        "Tissue": "Cholangiocarcinoma",
        "Model": "CTG-1420",
        "RON_Variant": "WT",
        "p_RON_Score": "3",
        "RON_Score": "2",
        "Patient_Treatments": "",
        "PDX_Model_TGI": "",
        "Tumor_status": "Local metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "Not available",
        "Treatment_history": "Not available",
        "Ethnicity": "Caucasian",
        "Alias": "POS-14100A",
        "Passage": "P3"
    },
    {
        "Tissue": "Cholangiocarcinoma",
        "Model": "CTG-2218",
        "RON_Variant": "165",
        "p_RON_Score": "3",
        "RON_Score": "3",
        "Patient_Treatments": "",
        "PDX_Model_TGI": "1. Cetuximab - 66% (20mpk)2. Docetaxel - 126% (20mpk)3. Irinotecan - 157% (100mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "First diagnosis",
        "Treatment_history": "Naive",
        "Ethnicity": "Caucasian",
        "Alias": "POS-16087A",
        "Passage": "P3"
    },
    {
        "Tissue": "Cholangiocarcinoma",
        "Model": "CTG-2246",
        "RON_Variant": "155",
        "p_RON_Score": "3",
        "RON_Score": "4",
        "Patient_Treatments": "",
        "PDX_Model_TGI": "",
        "Tumor_status": "Metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "First diagnosis",
        "Treatment_history": "Naive",
        "Ethnicity": "Not available",
        "Alias": "POS-16050A",
        "Passage": "P3"
    },
    {
        "Tissue": "Cholangiocarcinoma",
        "Model": "CTG-2497",
        "RON_Variant": "155",
        "p_RON_Score": "4",
        "RON_Score": "4",
        "Patient_Treatments": "",
        "PDX_Model_TGI": "",
        "Tumor_status": "Primary",
        "Histology": "Carcinoma",
        "Diagnosis": "First diagnosis",
        "Treatment_history": "Naive",
        "Ethnicity": "Caucasian",
        "Alias": "TMR-175A",
        "Passage": "P3"
    },
    {
        "Tissue": "Cholangiocarcinoma",
        "Model": "CTG-2508",
        "RON_Variant": "165",
        "p_RON_Score": "4",
        "RON_Score": "3",
        "Patient_Treatments": "",
        "PDX_Model_TGI": "1. Irinotecan - 94% (100mpk)2. Paclitaxel - 68% (?mpk)",
        "Tumor_status": "Primary",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "Not available",
        "Treatment_history": "Not available",
        "Ethnicity": "Not available",
        "Alias": "POS-16234A",
        "Passage": "P3"
    },
    {
        "Tissue": "Cholangiocarcinoma",
        "Model": "CTG-2619",
        "RON_Variant": "165",
        "p_RON_Score": "3",
        "RON_Score": "1",
        "Patient_Treatments": "",
        "PDX_Model_TGI": "",
        "Tumor_status": "Primary",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "First diagnosis",
        "Treatment_history": "Naive",
        "Ethnicity": "Black or African American",
        "Alias": "TMR-246A",
        "Passage": "P3"
    },
    {
        "Tissue": "Cholangiocarcinoma",
        "Model": "CTG-2740",
        "RON_Variant": "165",
        "p_RON_Score": "1",
        "RON_Score": "1",
        "Patient_Treatments": "",
        "PDX_Model_TGI": "",
        "Tumor_status": "Metastatic",
        "Histology": "Not available",
        "Diagnosis": "Not available",
        "Treatment_history": "Naive",
        "Ethnicity": "Caucasian",
        "Alias": "TMR-317A",
        "Passage": "P3"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-0166",
        "RON_Variant": "WT",
        "p_RON_Score": "0",
        "RON_Score": "1",
        "Patient_Treatments": "1. Cisplatin/Docetaxel/Bevacizumab - Response",
        "PDX_Model_TGI": "1. Bevacizumab - 70% (5mpk)2. Cetuximab - 32% (4mpk)3. Cisplatin - 69% (2mpk)4. Paclitaxel - 72% (30mpk)5. Topotecan - 157% (1.5mpk)",
        "Tumor_status": "Primary",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "DM142",
        "Passage": "P7"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-0192",
        "RON_Variant": "160",
        "p_RON_Score": "2",
        "RON_Score": "4",
        "Patient_Treatments": "1. Carboplatin/Paclitaxel/Cetuximab - Response",
        "PDX_Model_TGI": "1. Cisplatin - 70% (5mpk)2. Erlotinib - 32% (4mpk)3. Paclitaxel - 28% (20mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "First diagnosis",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "PULM-024",
        "Passage": "P5"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-0838",
        "RON_Variant": "165",
        "p_RON_Score": "1",
        "RON_Score": "5",
        "Patient_Treatments": "1. Carboplatin/Paclitaxel - No response2. Irinotecan/Pemetrexed/Bevacizumab - Responded; then progressed",
        "PDX_Model_TGI": " ",
        "Tumor_status": "Metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-10006B",
        "Passage": "P4"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-0852",
        "RON_Variant": "WT",
        "p_RON_Score": "1",
        "RON_Score": "4",
        "Patient_Treatments": "1. Carboplatin/Pemetrexed/Bevacizumab - Response2. Crizotinib - Response",
        "PDX_Model_TGI": "1. Alectinib - 225% (6mpk)2. Carboplatin/Paclitaxel - 53% (50mpk/10mpk)3. Crizotinib - 70% (20mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-12037A",
        "Passage": "P4"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-1012",
        "RON_Variant": "WT",
        "p_RON_Score": "1",
        "RON_Score": "3",
        "Patient_Treatments": "1. Carboplatin/Paclitaxel - Responded2. Doxorubicin - Responded3. Liposomal doxorubicin - Responded",
        "PDX_Model_TGI": "1. Carboplatin/Paclitaxel - 106% (50mpk/10mpk)2. Cisplatin/Pemetrexed - 152% (5mpk/100mpk)3. Docetaxel - 68% (20mpk)4. Everolimus - 86% (20mpk)5. Sunitinib - 82% (40mpk)6. Temozolomide - 134% (100mpk)",
        "Tumor_status": "Local metastatic",
        "Histology": "Sarcomatoid adenocarcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-13062A",
        "Passage": "P3"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-1269",
        "RON_Variant": "160",
        "p_RON_Score": "1",
        "RON_Score": "3",
        "Patient_Treatments": "1. Carboplatin/Pemetrexed/Bevacizumab - Responded2. Crizotinib - Responded",
        "PDX_Model_TGI": "",
        "Tumor_status": "Metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-12037R",
        "Passage": "P3"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-1444",
        "RON_Variant": "165",
        "p_RON_Score": "1",
        "RON_Score": "1",
        "Patient_Treatments": "1. Carboplatin/Nab-paclitaxel - Responded",
        "PDX_Model_TGI": "",
        "Tumor_status": "Metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "First diagnosis",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-14092A",
        "Passage": "P4"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-1502",
        "RON_Variant": "165",
        "p_RON_Score": "1",
        "RON_Score": "5",
        "Patient_Treatments": "1. Carboplatin/Docetaxel - N/A",
        "PDX_Model_TGI": "1. Carboplatin/Gemcitabine/Bevacizumab - 89% (20/25/100mpk)2. Carboplatin/Paclitaxel - 40% (50/10mpk)3. Carboplatin/Pemetrexed/Bevacizumab - 55% (100/25/20mpk)4. Carboplatin/Vinorelbine/Bevacizumab - 111% (20/25/5mpk)5. Gemcitabine/Nab-paclitaxel - 95% (20/100mpk)6. Irinotecan - 61% (100mpk)7. Paclitaxel - 79% (30mpk)8. Pemetrexed - 16% (100mpk)9. Vinorelbine - 74% (5mpk)",
        "Tumor_status": "Local metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "First diagnosis",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-14142A",
        "Passage": "P3"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-1612",
        "RON_Variant": "WT",
        "p_RON_Score": "1",
        "RON_Score": "4",
        "Patient_Treatments": "1. Cisplatin/Gemcitabine/Bevacizumab - N/A2. Carboplatin - N/A3. Bevacizumab - N/A",
        "PDX_Model_TGI": "1. Carboplatin/Pemetrexed - 154% (25/100mpk)2. Cetuximab - 40% (20mpk)3. Paclitaxel - 48% (20mpk)4. Ramucirumab - 143% (20mpk)5. Vinorelbine - 100% (5mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "First diagnosis",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-14179A",
        "Passage": "P2+1"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-1680",
        "RON_Variant": "WT",
        "p_RON_Score": "1",
        "RON_Score": "3",
        "Patient_Treatments": "1. Carboplatin/Pemetrexed - N/A",
        "PDX_Model_TGI": "1. Doxorubicin - 83% (3mpk)2. Etoposide - 22% (30mpk)3. Paclitaxel - 98% (20mpk)4. Vinorelbine - 131 (5mpk)",
        "Tumor_status": "Local metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-14060A",
        "Passage": "P3"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-1903",
        "RON_Variant": "WT",
        "p_RON_Score": "2",
        "RON_Score": "2",
        "Patient_Treatments": "1. Carboplatin/Etoposide - N/A2. Pemetrexed - N/A3. Experimental anti-PD1 therapy - No response4. Docetaxel - N/A",
        "PDX_Model_TGI": "",
        "Tumor_status": "Metastatic",
        "Histology": "Neuroendocrine adenocarcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "TMR-027A",
        "Passage": "P3"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-1932",
        "RON_Variant": "WT",
        "p_RON_Score": "1",
        "RON_Score": "3",
        "Patient_Treatments": "1. Cisplatin/Etoposide - Mixed response2. Carboplatin/Pemetrexed - Mixed response3. Ramucirumab/Docetaxel - Mixed response",
        "PDX_Model_TGI": "1. Gemcitabine - 139% (100mpk)2. Ipilimumab/Nivolumab - 16% (5/10mpk)3. Nivolumab - 1% (10mpk)4. Paclitaxel - 78% (20mpk)5. Vinorelbine - 153% (5mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "First diagnosis",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "MOS-15116A",
        "Passage": "P6"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-2143",
        "RON_Variant": "WT",
        "p_RON_Score": "2",
        "RON_Score": "3",
        "Patient_Treatments": "1. Durvalumab/Carboplatin/Nab-paclitaxel - N/A",
        "PDX_Model_TGI": "1. Doxorubicin - 133% (3mpk)2. Gemcitabine - 69% (100mpk)3. Pemetrexed - -5% (100mpk)4. Trametinib - 101% (1mpk)5. Vinorelbine - 75% (5mpk)",
        "Tumor_status": "Primary",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "First diagnosis",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-16030A",
        "Passage": "P3"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-2180",
        "RON_Variant": "WT",
        "p_RON_Score": "4",
        "RON_Score": "5",
        "Patient_Treatments": "1. Trastuzumab/Pertuzumab/Docetaxel - Responded2. Trastuzumab emtansine - Responded",
        "PDX_Model_TGI": "",
        "Tumor_status": "Metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "MOS-16056A",
        "Passage": "P3"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-2393",
        "RON_Variant": "WT",
        "p_RON_Score": "1",
        "RON_Score": "2",
        "Patient_Treatments": "1. Erlotinib - No response2. Osimertinib - Mixed response",
        "PDX_Model_TGI": "1. Carboplatin/Pemetrexed - 67% (25/100mpk)2. Gemcitabine - 120% (100mpk)3. Paclitaxel - 63% (10mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "First diagnosis",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-16069B",
        "Passage": "P3"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-2669",
        "RON_Variant": "165",
        "p_RON_Score": "4",
        "RON_Score": "2",
        "Patient_Treatments": "1. Ipilimumab/Nivolumab - Responded; then progressed",
        "PDX_Model_TGI": " ",
        "Tumor_status": "Primary",
        "Histology": "Carcinoma",
        "Diagnosis": "First diagnosis",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "TMR-276A",
        "Passage": "P3"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-2770",
        "RON_Variant": "WT",
        "p_RON_Score": "3",
        "RON_Score": "2",
        "Patient_Treatments": "",
        "PDX_Model_TGI": " ",
        "Tumor_status": "Metastatic",
        "Histology": "Squamous carcinoma",
        "Diagnosis": "Not available",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "TMR-345B",
        "Passage": "P3"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-2832",
        "RON_Variant": "155",
        "p_RON_Score": "2",
        "RON_Score": "1",
        "Patient_Treatments": "1. Pembrolizumab - N/A",
        "PDX_Model_TGI": " ",
        "Tumor_status": "Metastatic",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Not available",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "TMR-372A",
        "Passage": "P3"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-3044",
        "RON_Variant": "165",
        "p_RON_Score": "1",
        "RON_Score": "5",
        "Patient_Treatments": "1. Ceritinib - Responded; then progressed2. Alectinib - Responded; then progressed3. Carboplatin/Pemetrexed - Responded; then progressed",
        "PDX_Model_TGI": " ",
        "Tumor_status": "Metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "First diagnosis",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "MOS-17235A",
        "Passage": "P3"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-3122",
        "RON_Variant": "165",
        "p_RON_Score": "1",
        "RON_Score": "2",
        "Patient_Treatments": "1. Carboplatin/Pemetrexed - N/A2. Pemetrexed - N/A3. Pembrolizumab - N/A4. Carboplatin/Gemcitabine - N/A5. Tepotinib - N/A",
        "PDX_Model_TGI": " ",
        "Tumor_status": "Primary",
        "Histology": "Carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "T181-001A",
        "Passage": "P3"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-3190",
        "RON_Variant": "WT",
        "p_RON_Score": "2",
        "RON_Score": "1",
        "Patient_Treatments": "1. Pembrolizumab - No response2. Carboplatin/Pemetrexed - No response",
        "PDX_Model_TGI": " ",
        "Tumor_status": "Metastatic",
        "Histology": "Carcinoma with sarcomatoid features",
        "Diagnosis": "First diagnosis",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "T033-005",
        "Passage": "P4"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-3265",
        "RON_Variant": "WT",
        "p_RON_Score": "1",
        "RON_Score": "1",
        "Patient_Treatments": "1. Cisplatin/Gemcitabine - N/A",
        "PDX_Model_TGI": " ",
        "Tumor_status": "Metastatic",
        "Histology": "Sarcomatoid adenocarcinoma",
        "Diagnosis": "Not available",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "T032-022A",
        "Passage": "P3"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-3485",
        "RON_Variant": "WT",
        "p_RON_Score": "0",
        "RON_Score": "5",
        "Patient_Treatments": "1. Carboplatin/Pemetrexed/Pembrolizumab - N/A2. Pembrolizumab/Pemetrexed - N/A3. Aflibercept - N/A",
        "PDX_Model_TGI": " ",
        "Tumor_status": "Metastatic",
        "Histology": "Adenocarcinoma",
        "Diagnosis": "Pending",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "TMR-170A",
        "Passage": "P3"
    },
    {
        "Tissue": "NSCLC",
        "Model": "CTG-3514",
        "RON_Variant": "165",
        "p_RON_Score": "0",
        "RON_Score": "4",
        "Patient_Treatments": "1. Paclitaxel - No response",
        "PDX_Model_TGI": " ",
        "Tumor_status": "Metastatic",
        "Histology": "Not available",
        "Diagnosis": "Not available",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "T223-020A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-0152",
        "RON_Variant": "160",
        "p_RON_Score": "3",
        "RON_Score": "0",
        "Patient_Treatments": "1. Carboplatin/Docetaxel - N/A2. 5-Fluorouracil/Docetaxel/Cetuximab/Hydroxyurea - Responded3. Cetuximab (maintenance) - N/A",
        "PDX_Model_TGI": "1. 5-Fluorouracil - 1% (15mpk)2. Cetuximab - 58% (30mpk)3. Cisplatin - 50% (4mpk)4. Cisplatin/Cetuximab - 107% (30/2mpk)5. Paclitaxel - 40% (10mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Not available",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "DM171",
        "Passage": "P5"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-0566",
        "RON_Variant": "160",
        "p_RON_Score": "3",
        "RON_Score": "1",
        "Patient_Treatments": "1. 5-Fluorouracil/Cisplatin/Gefitinib - Responded",
        "PDX_Model_TGI": "1. 5-Fluorouracil/Carboplatin/Cetuximab - 13% (50/40/20mpk)2. Carboplatin/Everolimus - 125% (40/15mpk)3. Cetuximab/Bevacizumab - -51% (20/20mpk)4. Cetuximab/Docetaxel - 68% (40/20mpk)5. Cetuximab/Nab-paclitaxel - 28% (40/100mpk)6. Cetuximab/Pemetrexed/Bevacizumab - 107% (100/20/20mpk)7. Erlotinib - -75% (50mpk)8. Gemcitabine - 44% (?mpk)9. Gemcitabine/Bevacizumab - 75% (100/20mpk)10. Lapatinib/Pemetrexed - -65% (50/100mpk)11. Lapatinib/Sunitinib - -62% (50/40mpk)12. Pazopanib - 166% (1.25mpk)13. Trabectedin - 166% (0.15mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-11003A",
        "Passage": "P5"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-0674",
        "RON_Variant": "WT",
        "p_RON_Score": "4",
        "RON_Score": "0",
        "Patient_Treatments": "1. Cisplatin/Docetaxel/Bevacizumab - N/A2. Carboplatin/Paclitaxel - N/A",
        "PDX_Model_TGI": "1. Cetuximab - 68% (30mpk)2. Cisplatin - 2% (2mpk)3. Cisplatin/Cetuximab - 56% (30/2mpk)4. Irinotecan/Cetuximab - 33% (100/40mpk)5. Irinotecan/Pemetrexed - 63% (100/100mpk)6. Lapatinib/Sunitinib - 42% (50/40mpk)7. Paclitaxel - 57% (10mpk)8. Temsirolimus - 13% (20mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-11016A",
        "Passage": "P5"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-0701",
        "RON_Variant": "160",
        "p_RON_Score": "2",
        "RON_Score": "0",
        "Patient_Treatments": "1. Cetuximab - No response2. Carboplatin/Cetuximab - N/A3. Docetaxel - N/A",
        "PDX_Model_TGI": "1. Cetuximab - 76% (20mpk)2. Cisplatin - 35% (3mpk)3. Cisplatin/Cetuximab - 100% (3/20mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-11024A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-0798",
        "RON_Variant": "WT",
        "p_RON_Score": "2",
        "RON_Score": "0",
        "Patient_Treatments": "1. Gefitinib - No response2. Carboplatin/Paclitaxel/Trastuzumab - Responded; then progressed3. Regorafenib- No response4. Carboplatin/Docetaxel - Responded; then progressed5. Pemetrexed - Responded; then progressed6. Liposomal doxorubicin/Temsirolimus/Bevacizumab - Responded; then progressed7. Dasatinib/Paclitaxel/Bevacizumab - Mixed response",
        "PDX_Model_TGI": "1. Gemcitabine/Docetaxel - -17% (20/100mpk)2. Gemcitabine/Nab-paclitaxel/Bevacizumab - 108% (20/100/20mpk)3. Sorafenib - 83% (60mpk)4. Sunitinib - 65% (40mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Ductal adenocarcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-11072A",
        "Passage": "P5+1"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-0820",
        "RON_Variant": "WT",
        "p_RON_Score": "3",
        "RON_Score": "0",
        "Patient_Treatments": "1. Cisplatin - N/A2. 5-Fluorouracil/Carboplatin - N/A3. Cetuximab - N/A",
        "PDX_Model_TGI": "1. Cetuximab - 95% (30mpk)2. Cisplatin - 56% (7.5mpk)3. Cisplatin/Cetuximab - 95% (2/30mpk)4. Paclitaxel - 37% (10mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-12004A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-0840",
        "RON_Variant": "WT",
        "p_RON_Score": "5",
        "RON_Score": "4",
        "Patient_Treatments": "1. Cisplatin - No response2. Cetuximab/Docetaxel - Responded; then progressed3. Cisplatin/Vinorelbine - Mixed response",
        "PDX_Model_TGI": "1. 5-Fluorouracil/Carboplatin/Cetuximab - 134% (?mpk)2. Cetuximab - 68% (30mpk)3. Cisplatin - 16% (3mpk)4. Cisplatin/Gemcitabine - 120% (5/100mpk)5. Cisplatin/Cetuximab - 100% (2/30mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-12032A",
        "Passage": "P6"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-1130",
        "RON_Variant": "WT",
        "p_RON_Score": "3",
        "RON_Score": "0",
        "Patient_Treatments": "1. Cisplatin - Responded; then progressed2. 5-Fluorouracil/Cisplatin/Cetuximab - Responded",
        "PDX_Model_TGI": "1. 5-Fluorouracil/Cisplatin/Docetaxel - 95% (1.25/0.13/0.5mpk)2. Cisplatin/Gemcitabine - 43% (0.13/2.5mpk)3. Docetaxel - 137% (20mpk)4. Pemetrexed - -6% (2.5mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-13152A",
        "Passage": "P5"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-1131",
        "RON_Variant": "165",
        "p_RON_Score": "2",
        "RON_Score": "0",
        "Patient_Treatments": "1. Cisplatin - Responded; then progressed2. 5-Fluorouracil/Cisplatin/Cetuximab - Responded3. Afatinib - Responded",
        "PDX_Model_TGI": "1. Cisplatin - -29%(4mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "POS-13152B",
        "Passage": "P5"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-1994",
        "RON_Variant": "165",
        "p_RON_Score": "2",
        "RON_Score": "0",
        "Patient_Treatments": "1. Ifosfamide/Doxorubicin - Responded",
        "PDX_Model_TGI": "",
        "Tumor_status": "Metastatic",
        "Histology": "Spindle cell sarcoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "FCC-218A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-2020",
        "RON_Variant": "165",
        "p_RON_Score": "3",
        "RON_Score": "0",
        "Patient_Treatments": "1. Cetuximab - Responded",
        "PDX_Model_TGI": "",
        "Tumor_status": "Primary",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "TMR-044A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-2130",
        "RON_Variant": "165",
        "p_RON_Score": "4",
        "RON_Score": "1",
        "Patient_Treatments": "1. Cisplatin - No response2. Cetuximab - No response",
        "PDX_Model_TGI": "1. Capecitabine - 68% (200mpk)2. Carboplatin/Paclitaxel - 119% (25/20mpk)3. Paclitaxel - 113% (20mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "LON-002A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-2175",
        "RON_Variant": "WT",
        "p_RON_Score": "1",
        "RON_Score": "0",
        "Patient_Treatments": "",
        "PDX_Model_TGI": "",
        "Tumor_status": "Primary",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "TMR-087A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-2191",
        "RON_Variant": "WT",
        "p_RON_Score": "1",
        "RON_Score": "0",
        "Patient_Treatments": "",
        "PDX_Model_TGI": "",
        "Tumor_status": "Primary",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "TMR-091A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-2273",
        "RON_Variant": "165",
        "p_RON_Score": "3",
        "RON_Score": "2",
        "Patient_Treatments": "1. Carboplatin - N/A",
        "PDX_Model_TGI": "",
        "Tumor_status": "Primary",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "TMR-100A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-2318",
        "RON_Variant": "WT",
        "p_RON_Score": "3",
        "RON_Score": "1",
        "Patient_Treatments": "1. Cisplatin - No response",
        "PDX_Model_TGI": "",
        "Tumor_status": "Metastatic",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "LON-007A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-2324",
        "RON_Variant": "WT",
        "p_RON_Score": "3",
        "RON_Score": "1",
        "Patient_Treatments": "1. Cisplatin - No response",
        "PDX_Model_TGI": "",
        "Tumor_status": "Local metastatic",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Not available",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "LON-006A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-2344",
        "RON_Variant": "165",
        "p_RON_Score": "3",
        "RON_Score": "5",
        "Patient_Treatments": "1. 5-Fluorouracil/Cisplatin - No response",
        "PDX_Model_TGI": "1. Cetuximab - 147% (20mpk)2. Cetuximab/Paclitaxel - 101% (20/10mpk)3. Gemcitabine - 56% (100mpk)4. Methotrexate - 24% (5mpk)5. Paclitaxel - 89% (10mpk)",
        "Tumor_status": "Metastatic",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "First diagnosis",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "LON-008A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-2352",
        "RON_Variant": "WT",
        "p_RON_Score": "3",
        "RON_Score": "0",
        "Patient_Treatments": "",
        "PDX_Model_TGI": "1. Pembrolizumab - -10 (5mpk)",
        "Tumor_status": "Primary",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "TMR-094A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-2519",
        "RON_Variant": "WT",
        "p_RON_Score": "3",
        "RON_Score": "0",
        "Patient_Treatments": "1. Cisplatin - No response2. Tremelimumab - N/A",
        "PDX_Model_TGI": "1. 5-Fluorouracil - -14% (50mpk)2. Cetuximab - 32% (20mpk)3. Cisplatin - 2% (5mpk)4. Paclitaxel - -87% (10mpk)",
        "Tumor_status": "Local metastatic",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "LON-007A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-2715",
        "RON_Variant": "WT",
        "p_RON_Score": "3",
        "RON_Score": "3",
        "Patient_Treatments": "1. Cisplatin - N/A",
        "PDX_Model_TGI": "1. Cisplatin - 100% (5mpk)2. Doxorubicin - -35% (3mpk)3. Gemcitabine - 98% (100mpk)4. Paclitaxel - -98% (10mpk)",
        "Tumor_status": "Local metastatic",
        "Histology": "Carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "LON-011A",
        "Passage": "P1"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-2909",
        "RON_Variant": "160",
        "p_RON_Score": "3",
        "RON_Score": "4",
        "Patient_Treatments": "1. Cisplatin - N/A",
        "PDX_Model_TGI": "1. 5-Fluorouracil - 24% (50mpk)2. Cetuximab - 60% (20mpk)3. Cisplatin - 3% (5mpk)4. Paclitaxel - 55% (10mpk)",
        "Tumor_status": "Primary",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "LON-012A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-2989",
        "RON_Variant": "WT",
        "p_RON_Score": "1",
        "RON_Score": "2",
        "Patient_Treatments": "1. 5-Fluorouracil/Cisplatin/Docetaxel - No response2. Carboplatin - N/A3. Pembrolizumab - N/A4. Cetuximab - N/A",
        "PDX_Model_TGI": "",
        "Tumor_status": "Local metastatic",
        "Histology": "Carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "TMR-463A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-3046",
        "RON_Variant": "WT",
        "p_RON_Score": "4",
        "RON_Score": "3",
        "Patient_Treatments": "",
        "PDX_Model_TGI": "",
        "Tumor_status": "Primary",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "TMR-494A",
        "Passage": "P4"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-3105",
        "RON_Variant": "155",
        "p_RON_Score": "2",
        "RON_Score": "5",
        "Patient_Treatments": "1. Pembrolizumab - N/A2. Carboplatin/Paclitaxel - N/A3. Experimental CDK4i/Cetuximab - N/A",
        "PDX_Model_TGI": "",
        "Tumor_status": "Local metastatic",
        "Histology": "Squamous carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "TMR-523A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-3130",
        "RON_Variant": "WT",
        "p_RON_Score": "2",
        "RON_Score": "3",
        "Patient_Treatments": "1. Cisplatin - N/A",
        "PDX_Model_TGI": "",
        "Tumor_status": "Primary",
        "Histology": "Squamous cell carcinoma",
        "Diagnosis": "First diagnosis",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "T063-003A",
        "Passage": "P3"
    },
    {
        "Tissue": "Head and Neck",
        "Model": "CTG-3147",
        "RON_Variant": "160",
        "p_RON_Score": "4",
        "RON_Score": "2",
        "Patient_Treatments": "1. Cisplatin - N/A",
        "PDX_Model_TGI": "",
        "Tumor_status": "Primary",
        "Histology": "Squamous carcinoma",
        "Diagnosis": "Recurrent",
        "Treatment_history": "Pretreated",
        "Ethnicity": "Caucasian",
        "Alias": "T181-004A",
        "Passage": "P3"
    }
]